AC
CELG

Abbrea Capital’s Celgene Corp CELG Stock Holding History

Abbrea Capital’s Portfolio CELG Stock Details CELG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-2,800
Closed -$251K – 175
2018
Q3 		$251K Buy
2,800
+215
+8% +$19K 0.07% 163
2018
Q2 		$205K Sell
2,585
-1,557
-38% -$129K 0.06% 166
2018
Q1 		$370K Buy
4,142
+125
+3% +$12K 0.12% 128
2017
Q4 		$419K Sell
4,017
-1,872
-32% -$211K 0.14% 116
2017
Q3 		$859K Buy
5,889
+595
+11% +$81K 0.32% 79
2017
Q2 		$688K Buy
5,294
+85
+2% +$10.4K 0.27% 84
2017
Q1 		$648K Sell
5,209
-100
-2% -$12K 0.26% 86
2016
Q4 		$615K Buy
+5,309
New +$591K 0.29% 84

Other funds holding CELG

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Abbrea Capital's CELG Position: Q4 2018 in Review

Abbrea Capital sold out of Celgene Corp (CELG) in Q4 2018, closing a stake of 2,800 shares — an estimated $251K sold.

Abbrea Capital first reported a position in CELG in Q4 2016 and held it in 8 quarters. The position peaked at $859K in Q3 2017. 1,317 funds tracked by Wall St. Rank hold CELG as of Q4 2018.

  • Abbrea Capital reported no remaining Celgene Corp position as of Q4 2018 after selling out during the quarter.
  • Abbrea Capital sold 2,800 Celgene Corp shares in Q4 2018, an estimated $251K.
  • Abbrea Capital first reported a position in Celgene Corp in Q4 2016 and held it in 8 quarters.
  • Abbrea Capital's Celgene Corp position peaked at $859K in Q3 2017.
  • 1,317 funds tracked by Wall St. Rank held Celgene Corp as of Q4 2018.

Based on Abbrea Capital's 13F filing for Q4 2018, filed 5 Feb 2019.